title: Activity of guanylyl cyclase activators on the reaction of tracheal smooth muscle contraction.
abstract: BACKGROUND
  The subject of the study compare the influences of YC-1 guanylyl cyclase activator with ODQ guanylyl cyclase inhibitor on the tracheal smooth muscle contraction induced by carbachol. The study specified the influence of increasing concentrations of soluble guanylyl cyclase activators YC-1 and 8Br cGMP on the reaction of tracheal smooth muscle contraction released by carbachol. The author also examined the effect of increasing concentrations of soluble guanylyl cyclase inhibitor ODQ on the concentration-effect curves for carbachol.
  
  
  METHODS
  Testing was conducted on an isolated trachea of both sexes of Wistar rats with weight ranging between 350 g and 450 g. Tracheas were prepared in accordance with the Akcasu (1959) method in Szadujkis-Szadurski (1996) modification. Concentration-effect curves were determined with the use of cumulated concentration method, in accordance with the van Rossum method (1963) in Kenakin (2006) modification.
  
  
  RESULTS
  According to conducted testing, activation of soluble guanylyl cyclase with the use of YC-1 and 8Br cGMP caused reduced reaction of the tracheal smooth muscle with carbachol on average to 80%. Comparing concentration-effect curves for carbachol before and after the use of 8Br cGMP, similar results were obtained for those released by YC-1. On the other hand, increasing concentrations of guanylyl cyclase inhibitor - ODQ cause shift of curves to the left, decrease of EC(50) value and an increase of maximum reaction to carbachol.
  
  
  CONCLUSIONS
  Carbachol, depending on concentration, causes tracheal smooth muscle contraction. According to testing, we can confirm that activation of guanylyl cyclase leads to reduction of the reaction of tracheal smooth muscle to carbachol on average up to 80%
authors.affiliation: Department of Pharmacology and Therapy, Collegium Medicum in Bydgoszcz. izaglaza@gmail.com
authors.forename: Izabela
authors.initials: I
authors.lastname: Glaza
authors.forename: Leszek
authors.initials: L
authors.lastname: Szadujkis-Szadurski
authors.forename: Rafał
authors.initials: R
authors.lastname: Szadujkis-Szadurski
authors.forename: Marta
authors.initials: M
authors.lastname: Gajdus
authors.forename: Alicja
authors.initials: A
authors.lastname: Rzepka
authors.forename: Natalia
authors.initials: N
authors.lastname: Gurtowska
mesh_terms: D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D020536:Enzyme Activators / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006162:Guanylate Cyclase / Q000378:metabolism*; D007191:Indazoles / Q000494:pharmacology*; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects* / Q000201:enzymology; D010069:Oxadiazoles / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014132:Trachea / Q000187:drug effects* / Q000201:enzymology
chemical_list: C095284:1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D007191:Indazoles; D010069:Oxadiazoles; D011810:Quinoxalines; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; C016276:8-bromocyclic GMP; D002217:Carbachol; D006162:Guanylate Cyclase; D006152:Cyclic GMP